Dear Friends:

In 2012, after losing my father to Alzheimer’s disease and seeing my mother begin to show early signs, I partnered with the Alzheimer’s Association to found Part the Cloud with a singular mission: to fund research with the highest probability of slowing, stopping or ultimately curing Alzheimer’s disease.

Since our inception, I have been overwhelmed by the support we have received from so many which has allowed us to grow from a local Bay Area event into a global movement, funding 39 clinical trials across the globe. Most grants support middle and latter clinical trials, but there are few funding sources to support the earlier phase studies needed to test drug treatments in humans. Part the Cloud addresses this critical gap, supporting early phase clinical studies and helping accelerate the transition of findings from the laboratory into possible therapies.

Part the Cloud not only provides key funding for early-phase clinical trials, but we also serve as a catalyst in helping researchers receive additional funding for their work. After receiving initial funding from PTC, grant recipients have gone on to receive over $259 million in follow up funding from the NIH, NIA and venture capital.

Recently, I was thrilled to announce our newest partnership with Bill Gates, with the goal to double our research investment to $60 million in just one year. This strategic funding will help propel high-risk, high-reward research aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia and get us one step closer to finding a treatment or cure for Alzheimer’s disease in our lifetime.

Part the Cloud is truly making a difference in the field of Alzheimer’s research, and after seeing the disease claim both of my parents after suffering for 20 years collectively, I am even more grateful to our generous supporters for their commitment to our mission.

Thank you for your support, and together, we will Part the Cloud!

Warmly,

Mikey Hoag

Founder, Part the Cloud
**METABOLIC FUNCTION**

**Stephen Cunnane, Ph.D.** University of Sherbrooke - Quebec, Canada  
**RCT With a Ketone Ester Drink in MCI**  
*Two-time grant winner*

**Mitchel Kling, M.D.** University of Pennsylvania - Philadelphia, PA  
A Biomarker-Based Trial of Plasmalogen Repletion in MCI/AD

**Stefano Sensi, M.D., Ph.D.** Universita degli Studi Gabriele d’Annunzio di Chieti e Pescara - Italy  
Extenzin-Based Therapy for MCI Subjects

**Paul Edison, M.B.B.S, F.R.C.P., Ph.D.** Imperial College London - London, UK  
Evaluating Oral Semaglutide as a Treatment for Alzheimer’s Disease

**Giulio Maria Pasinetti, M.D., Ph.D.** Icahn School of Medicine at Mount Sinai - New York, NY  
BDPP Treatment for Mild Cognitive Impairment and Prediabetes

**Russell Swerdlow, M.D.** University of Kansas Medical Center - Fairway, KS  
Trial of Oxaloacetate in Alzheimer’s Disease (TOAD) Study

**AMYLOID AND TAU**

**Adam L. Boxer, M.D., Ph.D.** University of California at San Francisco - San Francisco, CA  
Phase I Multiple Ascending Dose Trial of the MT Stabilizer TPI–287 for AD

**Dale E. Bredesen, M.D.** Buck Institute for Research on Aging - Novato, CA  
An Exploratory Safety, PK/PD, and Preliminary Efficacy Study of F03 in MCI

**Tim West, Ph.D.** C2N Diagnostics - St. Louis, MO  
A Single Ascending-Dose, Double-Blinded, Placebo-Controlled Study of an Anti-Tau Antibody

**Dieter Willbold, Ph.D.** Research Center Juelich GmbH - Germany  
Placebo Controlled Multi-Ascending Dose [Targeting Protein Aggregation] Phase 1 Study in Healthy Volunteers
IMMUNE RESPONSE, MISFOLDED PROTEINS AND GROWTH FACTORS

Steven Arnold, M.D. Massachusetts General Hospital - Boston, MA
Biomarker and Neural System Effects in Calcineurin Inhibition with Tacrolimus

Frantz Hefti, Ph.D. Proclara Biosciences - Cambridge, MA
Phase I Study With NPT088, a Fusion Protein to Treat Alzheimer’s Disease

Joseph Foss, M.D. NeuroTherapia, Inc. - Cleveland, OH
A Phase I Single Ascending Dose Safety and Pharmacokinetic Study of NTRX-07

John Sedivy, Ph.D. Brown University - Providence, RI
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of Alzheimer’s Disease

Mark Tuszynski, M.D. University of California at San Diego - San Diego, CA
A Clinical Trial of BDNF Gene Therapy in Alzheimer’s Disease

Linda Van Eldik, Ph.D. University of Kentucky - Lexington, KY
Phase 1b MAD Study of a Novel Drug (MW189) Targeting Neuroinflammation

Manfred Windisch, Ph.D. Neurokinine Therapeutics, LLC - Philadelphia, PA
Phase I Study of MW150: Novel Stress Kinase Inhibitor Candidate

Getting potential treatments faster: Propelling high-risk, high-reward research into clinical trials that are aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia.

Maurice Zauderer, Ph.D. Vaccinex, Inc. - Rochester, NY
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease

CELL SIGNALING AND COMMUNICATION

Frank Longo, M.D. Stanford University, and Anne Longo, Pharmatrophix, Inc. - Stanford, CA
Phase I Trial for P75 Receptor Ligand

Paul A. Newhouse, M.D. Vanderbilt University - Nashville, TN
M1-PAM VU319 Effects on Network Connectivity in MCI: A POC Study *Two-time grant winner*

Keith Vossel, M.D., M.S. University of California at San Francisco and Gladstone Institute for Neurological Disease - San Francisco, CA
Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability

Charbel Moussa, Ph.D. Georgetown University - Washington, D.C.
Bosutinib Effects on Safety, Biomarkers and Clinical Outcomes in DLB

Ahmad Salehi, M.D., Ph.D. Palo Alto Institute for Research and Education, Inc. - Palo Alto, CA
Improving β2 Adrenergic Signaling in Alzheimer’s Disease

Nawaf Yassi, M.D., Ph.D. University of Melbourne - Australia
S-Adenosyl Methionine for Alzheimer’s Disease

DRUG PIPELINE

Getting potential treatments faster: Propelling high-risk, high-reward research into clinical trials that are aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia.

Maurice Zauderer, Ph.D. Vaccinex, Inc. - Rochester, NY
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease

CELL SIGNALING AND COMMUNICATION

Frank Longo, M.D. Stanford University, and Anne Longo, Pharmatrophix, Inc. - Stanford, CA
Phase I Trial for P75 Receptor Ligand

Paul A. Newhouse, M.D. Vanderbilt University - Nashville, TN
M1-PAM VU319 Effects on Network Connectivity in MCI: A POC Study *Two-time grant winner*

Keith Vossel, M.D., M.S. University of California at San Francisco and Gladstone Institute for Neurological Disease - San Francisco, CA
Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability

Charbel Moussa, Ph.D. Georgetown University - Washington, D.C.
Bosutinib Effects on Safety, Biomarkers and Clinical Outcomes in DLB

Ahmad Salehi, M.D., Ph.D. Palo Alto Institute for Research and Education, Inc. - Palo Alto, CA
Improving β2 Adrenergic Signaling in Alzheimer’s Disease

Nawaf Yassi, M.D., Ph.D. University of Melbourne - Australia
S-Adenosyl Methionine for Alzheimer’s Disease

Cases are shown in black, except for one study not advanced.

* Studies not advanced
### RESCUE AND NEURODEGENERATION

The Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease challenge aims to accelerate the discovery and testing of innovative compounds to be used for interventions in the earliest stages of neurodegeneration—dementia—Alzheimer’s disease. Presently, there are no effective interventions to delay or prevent the progression of the neurodegenerative processes that underlie the disabling symptoms of Alzheimer’s dementia.

From 45 proposals submitted from two countries, six researchers were awarded $1 million each to develop their proposals over a two-year period.

**Robertta Diaz Brinton, Ph.D.** University of Arizona - Tucson, AZ  
*Advancing Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s*

**Rafael de la Torre, PharmD, Ph.D.** Institute Mar of Medical Investigations - Barcelona, Spain  
*Cognitive Decline in Early Stages of AD After EGCG and a Multimodal Therapy*

**Xue Hua, Ph.D.** Athira Pharma, Inc. - Seattle, WA  
*Phase 2a Alzheimer’s Trials of a Novel Neurotrophic Activator, NDX-1017*

**Paul A. Newhouse, M.D.** Vanderbilt University - Nashville, TN  
*M1-PAM VU319 Effects on Network Connectivity in MCI: A POC Study*  
*Two-time grant winner*

### CHALLENGES

**NEUROINFLAMMATION**

A first-of-its kind competition, the Part the Cloud Neuroinflammation Challenge was created to accelerate therapeutics and deepen understanding of neurodegeneration to be used in early clinical trials. Scientists around the world were invited to submit proposals that could translate into human trials of treatments targeting neuroinflammation with the goal of improving cognition in individuals with neurodegenerative diseases.

From 60 proposals submitted from 14 countries, four researchers were awarded $1 million each to develop their proposals over a two-year period. After two years, projects were evaluated, and the most outstanding project was awarded an additional $3 million to take it and the field to the next level.

**Anthony Andrew Oliva, Ph.D.** Longeveron, LLC - Miami, FL  
*Winning proposal: Mesenchymal Stem Cell Therapy for Neuroinflammation in Alzheimer’s Disease*

*After two years, this study was shown to have made the most progress and received an additional award of $3 million.*

**Stephen M. Strittmatter, M.D., Ph.D.** Yale University - New Haven, CT  
*Silent Allosteric Modulation of mGluR5 for Alzheimer’s Disease*

**Raymond Tesi, M.D.** INmune Bio - La Jolla, CA  
*A biomarker directed study to reduce inflammation in Alzheimer’s disease*

### CELL SENESCENCE

**James Kirkland, M.D., Ph.D.** Mayo Clinic - Rochester, MN  
*ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer’s Disease*

### VASCULAR AND OXIDATIVE STRESS

**Whitney Wharton, Ph.D.** Emory University - Atlanta, GA  
*Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s*

**Krista L. Lanctot, Ph.D.** Sunnybrook Research Institute - Ontario, Canada  
*Linking GSH and Cognitive Response: A Pilot Phase 2a Study of NAC in VCIND*

---

### PART THE CLOUD

Part the Cloud keeps expenses low to ensure that over 93% of funds raised directly support the most groundbreaking Alzheimer’s research.

<table>
<thead>
<tr>
<th>Total Expenses</th>
<th>Total Revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,107,073.72</td>
<td>$30,143,238.22</td>
</tr>
</tbody>
</table>
In late 2019, Part the Cloud announced an exciting partnership with Bill Gates, with the goal to double our investment in Alzheimer’s research to $60 million. The Alzheimer’s Association, through Part the Cloud, is taking on the challenge of raising $20 million, and once we reach that mark, Bill Gates will provide a $10 million match, allowing us to double our clinical research investment to $60 million in just one year.

This funding will allow us to propel high-risk, high-reward research aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia. These research grants will focus on the following three topic areas:

**Mitochondria**
How brain cells use energy and fuel (mitochondria, bioenergetics and metabolism)

**Autophagy / Clearance**
How brain cells remove waste and debris to avoid protein clumping

**Vascular Contributions**
How blood supply in the brain is maintained

---

**GATES AND PART THE CLOUD 2020 CHALLENGE**

In late 2019, Part the Cloud announced an exciting partnership with Bill Gates, with the goal to double our investment in Alzheimer’s research to $60 million. The Alzheimer’s Association, through Part the Cloud, is taking on the challenge of raising $20 million, and once we reach that mark, Bill Gates will provide a $10 million match, allowing us to double our clinical research investment to $60 million in just one year.

This funding will allow us to propel high-risk, high-reward research aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia. These research grants will focus on the following three topic areas:

**Mitochondria**
How brain cells use energy and fuel (mitochondria, bioenergetics and metabolism)

**Autophagy / Clearance**
How brain cells remove waste and debris to avoid protein clumping

**Vascular Contributions**
How blood supply in the brain is maintained

---

**We need your help to reach our goal**, so please consider making a donation to support Part the Cloud and our mission to find a treatment or cure for Alzheimer’s disease in our lifetime.

Learn more and make a donation at [alz.org/speed](http://alz.org/speed)
Part the Cloud is part of the Alzheimer’s Association’s robust research platform, the largest nonprofit research program focused on Alzheimer’s and dementia globally. This research program actively brings together government, academia, companies and philanthropists to support the efforts of researchers and accelerate science to achieve effective treatments.

“Part the Cloud propels the global research community and allows it to explore innovative avenues of research that can accelerate needed treatments,” said Maria C. Carrillo, Ph.D., chief science officer, Alzheimer’s Association. “Bill Gates and Mikey Hoag’s commitment to the Alzheimer’s Association demonstrates the urgency with which we must pursue innovative ideas that could be game changers for the tens of millions affected by Alzheimer’s disease worldwide”.

JOIN US. TOGETHER, WE WILL
PART THE CLOUD

alz.org/partthecloud